Publications by authors named "Pooja M Dhupkar"
Mol Cancer Ther
March 2015
Article Synopsis
- Primary and acquired resistance to antibody immunotherapies complicates cancer treatment, with the study highlighting that proteolytic inactivation of antibodies is a key factor in cancer immune evasion.
- A specific cleavage in the IgG1 structure of trastuzumab impairs its effectiveness against cancer cells, particularly when the cells produce the IgG-degrading enzyme IdeS.
- The researchers developed an antibody (mAb2095-2) that targets the cleaved antibodies, restoring their cancer-fighting abilities in lab and animal models, suggesting a new therapeutic approach to enhance the efficacy of existing antibody treatments.
